+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Global Induced Pluripotent Stem Cell (iPSC) Industry Report, 2022

  • PDF Icon

    Report

  • 327 Pages
  • July 2022
  • Region: Global
  • BioInformant
  • ID: 5024881

Since the discovery of induced pluripotent stem cell (iPSC) technology in 2006, significant progress has been made in stem cell biology and regenerative medicine. New pathological mechanisms have been identified and explained, new drugs identified by iPSC screens are in the pipeline, and the first clinical trials employing human iPSC-derived cell types have been initiated. iPSCs can be used to explore the causes of disease onset and progression, create and test new drugs and therapies, and treat previously incurable diseases.

Today, methods of commercializing induced pluripotent stem cells (iPSCs) include:

  • Cell Therapy: iPSCs are being explored in a diverse range of cell therapy applications for the purpose of reversing injury or disease.
  • Disease Modelling: By generating iPSCs from patients with disorders of interest and differentiating them into disease-specific cells, iPSCs can effectively create disease models “in a dish.”
  • Drug Development and Discovery:iPSCs have the potential to transform drug discovery by providing physiologically relevant cells for compound identification, target validation, compound screening, and tool discovery.
  • Personalized Medicine: The use of techniques such as CRISPR enable precise, directed creation of knock-outs and knock-ins (including single base changes) in many cell types. Pairing iPSCs with genome editing technologies is adding a new dimension to personalized medicine.
  • Toxicology Testing: iPSCs can be used for toxicology screening, which is the use of stem cells or their derivatives (tissue-specific cells) to assess the safety of compounds or drugs within living cells.

Other applications of iPSCs include their use as research products, as well as their integration into 3D bioprinting, tissue engineering, and clean meat production. Technology allowing for the mass-production and differentiation of iPSCs in industrial-scale bioreactors is also advancing at breakneck speed.

iPSC Derived Clinical Trials

The first clinical trial using iPSCs started in 2008, and today, that number has surged worldwide. Most of the current clinical trials do not involve the transplant of iPSCs into humans, but rather, the creation and evaluation of iPSC lines for clinical purposes. Within these trials, iPSC lines are created from specific patient populations to determine if these cell lines could be a good model for a disease of interest. 

The therapeutic applications of induced pluripotent stem cells (iPSCs) have also surged in recent years. Since the discovery of iPSCs in 2006, it took only seven years for the first iPSC-derived cell product to be transplanted into a human patient in 2013. Since then, iPSC-derived cells have been used within a rapidly growing number of preclinical studies, physician-led studies, and formal clinical trials worldwide.

iPS Cell Market Competitors

In addition to the iPSC cell therapy developers, there are an ever-growing number of competitors who are commercializing iPSC-derived products for use in drug development and discovery, disease modeling, toxicology testing, and personalized medicine, as well as tissue engineering, 3D bioprinting, and clean meat production.

Across the broader iPSC sector, FUJIFILM CDI (FCDI) is one of the largest and most dominant players. Cellular Dynamics International (CDI) was founded in 2004 by Dr. James Thomson at the University of Wisconsin-Madison, who in 2007 derived iPSC lines from human somatic cells for the first time. The feat was accomplished simultaneously by Dr. Shinya Yamanaka’s lab in Japan. FUJIFILM acquired CDI in April 2015 for $307 million. Today, the combined company is the world’s largest manufacturer of human cells created from iPSCs for use in research, drug discovery and regenerative medicine applications.

Another iPSC specialist is ReproCELL, a company that was established as a venture company originating from the University of Tokyo and Kyoto University in 2009. It became the first company worldwide to make iPSC products commercially available when it launched its ReproCardio product, which are human iPSC-derived cardiomyocytes.

Within the European market, the dominant competitors are Evotec, Ncardia, and Axol Bioscience. Headquartered in Hamburg, Germany, Evotec is a drug discovery alliance and development partnership company. It is developing an iPSC platform with the goal to industrialize iPSC-based drug screening as it relates to throughput, reproducibility, and robustness. Today, Evotec’s infrastructure represents one of the largest and most advanced iPSC platforms globally.

Ncardia was formed through the merger of Axiogenesis and Pluriomics in 2017. Its predecessor, Axiogenesis, was founded in 2011 with an initial focus on mouse embryonic stem cell-derived cells and assays. When Yamanaka’s iPSC technology became available, Axiogenesis became the first European company to license it in 2010. Today, the combined company (Ncardia) is a global authority in cardiac and neural applications of human iPSCs.

Founded in 2012, Axol Bioscience is a smaller but noteworthy competitor that specializes in iPSC-derived products. Headquartered in Cambridge, UK, it specializes in human cell culture, providing iPSC-derived cells and iPSC-specific cell culture products.

Of course, the world’s largest research supply companies are also commercializing a diverse range of iPSC-derived products and services. Examples of these companies include Lonza, BD Biosciences, Thermo Fisher Scientific, Merck, Takara Bio, and countless others.  In total, at least 80 market competitors now offer various types of iPSC products, services, manufacturing technologies, and therapeutics.


iPSC Report Details

This global strategic report reveals all major market competitors worldwide, including their core technologies, strategic partnerships, and products under development. It covers the current status of iPSC research, biomedical applications, manufacturing technologies, patents, and funding events, as well as all known trials for the development of iPSC-derived cell therapeutics worldwide. Importantly, it profiles leading market competitors worldwide and presents a comprehensive market size breakdown for iPSCs by Application, Technology, Cell Type, and Geography (North America, Europe, Asia/Pacific, and Rest of World). It also presents total market size figures with projected growth rates through 2029.

Claim this global strategic report to become immediately informed about the iPSC market, without sacrificing weeks of unnecessary research or missing critical market opportunities.

Table of Contents

1. Report Overview
1.1 Statement of the Report
1.2 Executive Summary
2. Introduction
3. Current Status of iPSC Industry
3.1 Progress Made in Autologous Cell Therapy Using iPSCs
3.1.1 Examples of Autologous iPSC-Derived Cell Therapies in Development
3.2 Manufacturing Timeline for Autologous iPSC-Derived Cell Products
3.3 Cost of iPSC Production
3.4 Automation in iPSC Production
3.5 Allogeneic iPSCs Gaining Momentum
3.5.1 Ongoing Clinical Trials Involving Allogeneic iPSCs
3.6 Share of iPSC-Based Research Within the Overall Stem Cell Industry
3.7 Major Focus Areas of iPSC Companies
3.8 Commercially Available iPSC-Derived Cell Types
3.9 Relative Use of iPSC-Derived Cell Types in Toxicology Testing Assays
3.10 Currently Available iPSC Technologies
3.10.1 Brief Descriptions of Some Recently Introduced iPSC-Related Technologies
3.10.1.1 Nucleofector Technology
3.10.1.2 Opti-Ox Technology
3.10.1.3 Mogrify Technology
3.10.1.4 Transcription Factor-Based iPSC Differentiation Technology
3.10.1.5 Flowfect Technology
3.10.1.6 Technology for Mass Production of Platelets from Megakaryocytes
3.10.1.7 Synfire Technology
4. History of Induced Pluripotent Stem Cells (iPSCs)
4.1 First iPSC Generation from Mouse Fibroblasts, 2006
4.2 First Human iPSC Generation, 2007
4.3 Creation of Cira, 2010
4.4 First High-Throughput Screenining Using iPSCs, 2012
4.5 First iPSC Clinical Trial Approved in Japan, 2013
4.6 First iPSC-Rpe Cell Sheet Transplantation for Amd, 2014
4.7 Ebisc Founded, 2014
4.8 First Clinical Trial Using Allogeneic iPSCs for Amd, 2017
4.9 Clinical Trial for Parkinson’S Disease Using Allogeneic iPSCs, 2018
4.10 Commercial iPSC Plant Smart Established, 2018
4.11 First iPSC Therapy Center in Japan, 2019
4.12 First U.S.-Based Nih-Sponsored Clinical Trial Using iPSCs, 2019
4.13 Cynata Therapeutics’ World’S Largest Phase Iii Clinical Trial, 2020
4.14 Tools and Know-How to Manufacture iPSCs in Clinical Trials, 2021
4.15 Production of In-House iPSCs Using Peripheral Blood Cells, 2022
5. Research Publications on iPSCs
5.1 the Fast Growth in iPSC Publications
5.1.1 Pubmed Publications on Pathophysiological Research
5.1.2 Pubmed Papers in Reprogramming
5.1.3 Pubmed Papers in iPSC Differentiation
5.1.4 Pubmed Papers on the Use of iPSCs in Drug Discovery
5.1.5 Pubmed Papers on iPSC-Based Cell Therapy
5.2 Percent Share of Published Articles by Disease Type
5.3 Percent Share of Articles by Country
6. iPSC: Patent Landscape Analysis
6.1 Legal Status of iPSC Patents
6.2 Patents by Assignee Organization Type
6.3 Ownership of Patent Families by Assignee Type
6.4 Top Inventors of iPSC Patents
6.5 Top Ten iPSC Inventors
6.6 Most Cited Five iPSC Patents
6.7 Leading Patent Filing Jurisdictions
6.8 Number of Patent Families by Year of Filing
6.9 Patents Representing Different Disorders
6.10 iPSC Patents on Preparation Technologies
6.11 Patents on Cell Types Differentiated from iPSCs
6.12 Patent Application Trends Disease-Specific Technologies
7. iPSC: Clinical Trial Landscape
7.1 Literature and Database Search
7.2 Number of iPSC Clinical Trials by Year
7.3 iPSC Study Designs
7.3.1 Therapeutic and Non-Therapeutic Studies
7.3.2 Non-Therapeutic Clinical Trials by Use
7.3.2.1 Top Ten Countries With the Ongoing Non-Therapeutic Studies
7.3.2.2 Diseases Targeted by Non-Therapeutic Studies
7.3.3 Therapeutic Studies
7.3.3.1 Therapeutic Studies by Phase of Study
7.3.3.2 Therapeutic Studies by Disease Type
7.3.3.3 Examples of Therapeutic Interventional Studies
7.3.3.4 Future Outlook for Therapeutic Clinical Trials Using iPSCs
7.4 iPSC-Based Clinical Trials With Commercialization Potential
8. Research Funding for iPSCs
8.1 Value of Nih Funding for iPSC Research
8.2 Partial List of Nih Funded iPSC Research Projects in 2022
9. M&A, Collaborations & Funding Activities in iPSC Sector
9.1 Mergers and Acquisitions (M&A) in iPSC Sector
9.1.1 Evotec & Rigenerand
9.1.2 Catalent & Rheincell Therapeutics
9.1.3 Axol Bioscience & Censo Biotechnologies
9.1.4 Bayer AG & Bluerock
9.1.5 Pluriomics & Axiogenesis
9.2 Partnership/Collaboration/Licensing Deals in iPSC Sector
9.2.1 Evotec & Sernova
9.2.2 Evotec Se & Almirall, Sa
9.2.3 Quell Therapeutics & Cellistic
9.2.3.1 Terms of the Collaboration
9.2.4 Mdimmune & Yipscell
9.2.5 Edigene & Neukio Biotherapeutics
9.2.6 Matricelf & Ramot
9.2.7 Evotec & Boehringer Ingelheim
9.2.8 Plurityx, Pancella & Implant Therapeutics
9.2.9 Century Therapeutics & Bristol Myers Squibb
9.2.10 Terms of the Collaboration
9.2.11 Fujifilm Cellular Dynamics & Pheno Vista Biosciences
9.2.12 Metrion Biosciences & Bioqube Ventures
9.2.13 Cytovia Therapeutics & Cellectis
9.2.14 Exacis Biotherapeutics & Ccrm
9.2.15 Cynata Therapeutics & Fujifilm Corporation
9.2.16 Bone Therapeutics & Implant Therapeutics
9.2.17 Reprocell & Texcell
9.2.18 Jacobio & Herbecell
9.2.19 Neucyte & Kif1A.Org
9.2.20 Kite & Shoreline Biosciences
9.2.21 Neurophth Therapeutics & Hopstem Biotechnology
9.2.22 Allele Biotech & Cellatoz
9.2.23 Bluerock Therapeutics, Fujifilm Cellular Dynamics & Opsis Therapeutics
9.2.24 Newcells & Takeda
9.2.25 Biocentriq & Kytopen
9.2.26 Fujifilm Cellular Dynamics & Sana Biotechnology
9.2.27 Evotec & Medical Center Hamburg-Eppendorf (Uke)
9.2.28 Neucyte & Seaver Autism Center for Research and Treatment
9.2.29 Cytovia Therapeutics & National Cancer Institute
9.2.30 Mogrify & Mrc Laboratory of Molecular Biology
9.3 Venture Capital Funding and Ipos
9.3.1 Aspen Neuroscience
9.3.2 Axol Biosciences Ltd.
9.3.3 Thyas Co. Ltd.
9.3.4 Synthego
9.3.5 Cellino Biotech, Inc.
9.3.6 Curi Bio
9.3.7 Ncardia
9.3.8 Evotec Se
9.3.9 Bit.Bio
9.3.10 Clade Therapeutics
9.3.11 Shoreline Biosciences
9.3.12 Kytopen
9.3.13 Cytovia Therapeutics & Cytolynx
9.3.14 Treefrog Therapeutics
9.3.15 Hebecell Corporation
9.3.16 Neukio Biotherapeutics
9.3.17 Stemson Therapeutics
9.3.18 Vita Therapeutics
9.3.19 Century Therapeutics
9.3.20 Heartseed
9.3.21 Mogrify
9.3.22 Metrion Biosciences
9.3.23 Axol Biosciences
9.3.24 Axol Bioscience
9.3.25 Elevate Bio
9.3.26 Vita Therapeutics
10. Generation of Induced Pluripotent Stem Cells: An Overview
10.1 Reprogramming Factors
10.1.1 Pluripotency-Associated Transcription Factors and Their Functions
10.1.2 Different Combinations of Factors for Different Cell Sources
10.1.3 Delivery of Reprogramming Factors
10.2 Integrating iPSC Delivery Methods
10.2.1 Retroviral Vectors
10.2.2 Lentiviral Vectors
10.2.3 Piggybac (Pb) Transposon
10.3 Non-Integrative Delivery Systems
10.3.1 Adenoviral Vectors
10.3.2 Sendai Viral Vectors
10.3.3 Plasmid Vectors
10.3.4 Minicircles
10.3.5 Orip/Epstein-Barr Nuclear Antigen-1 (Ebna1) Based Episomes
10.3.6 Rna
10.3.7 Proteins
10.4 Comparison of Delivery Methods for Generating iPSCs
10.5 Genome Editing Technologies in iPSC Generation
10.5.1 Crispr/Cas9
11. Human iPSC Banking
11.1 Cell Sources for iPSC Banking
11.2 Reprogramming Methods Used in iPSC Banking
11.3 Factors Used in Reprogramming in Different Banks
11.4 Workflow in iPSC Banks
11.5 Existing iPSC Banks
11.5.1 California Institute for Regenerative Medicine (Cirm)
11.5.1.1 Cirm iPSC Repository
11.5.1.2 Key Partnerships Supporting Cirm’S iPSC Repository
11.6 Regenerative Medicine Program (Rmp)
11.6.1 Research Grade iPSC Lines for Orphan & Rare Diseases With Rmp
11.6.2 Rmp’S Stem Cell Translation Laboratory (Sctl)
11.7 Center for Ips Cell Research and Application (Cira)
11.8 Fit - Facility for Ips Cell Therapy
11.9 European Bank for Induced Pluripotent Stem Cells (Ebisc)
11.10 Korean Society for Cell Biology (Kscb)
11.11 Human Induced Pluripotent Stem Cell Initiative (Hipsci)
11.12 Riken - Bioresource Research Center (Brc)
11.13 Taiwan Human Disease iPSC Consortium
11.14 Wicell
12. Biomedical Applications of iPSCs
12.1 iPSCs in Basic Research
12.1.1 to Understand Cell Fate Control
12.1.2 to Understand Cell Rejuvenation
12.1.3 to Understand Pluripotency
12.1.4 to Study Tissue & Organ Development
12.1.5 to Produce Human Gametes from iPSCs
12.1.6 Providers of iPSC-Related Services for Researchers
12.2 iPSCs in Drug Discovery
12.2.1 Advantages
12.2.2 Drug Discovery for Cardiovascular Diseases Using iPSCs
12.2.3 Drug Discovery for Neurological Diseases Using iPSCs
12.2.4 Drug Discovery for Rare Diseases Using iPSCs
12.3 iPSCs in Toxicology Studies
12.3.1 Testing Drugs for Dili
12.3.2 Examples of Drugs Tested in iPSC-Derived Cells
12.3.3 Relative Use of iPSC-Derived Cell Types in Toxicity Testing Studies
12.4 iPSCs in Disease Modeling
12.4.1 Cardiovascular Diseases Modeled With iPSC-Derived Cells
12.4.1.1 Percent Share Utilization of iPSCs for Cardiovascular Disease Modeling
12.4.2 Modeling Liver Diseases Using iPSC-Derived Hepatocytes
12.4.3 iPSCs in Neurodegenerative Disease Modeling
12.4.4 iPSC-Derived Organoids for Modeling and Diseases
12.4.5 Cancer-Derived iPSCs
12.5 iPSCs in Cell-Based Therapies
12.5.1 Companies Focusing Only on iPSC-Based Cell Therapy
12.6 Other Novel Applications of iPSCs
12.6.1 iPSCs in Tissue Engineering
12.6.1.1 3D Bioprinting Techniques
12.6.1.2 Biomaterials
12.6.1.3 3D Bioprinting Strategies
2.6.1.4 Bioprinting iPSC-Derived Cells
12.6.2 iPSCs from Farm Animals
12.6.2.1 Porcine iPSCs
12.6.2.2 Bovine iPSCs
12.6.2.3 Ovine and Caprine iPSCs
12.6.2.4 Equine iPSCs
12.6.2.5 Avian iPSCs
12.7 iPSCs in Animal Conservation
12.7.1 iPSC Lines for the Preservation of Endangered Species of Animals
12.7.2 iPSCs in Wildlife Conservation
12.7.3 iPSCs in Cultured Meat
13. Market Overview
13.1 Global Market for iPSCs by Geography
13.2 Global Market for iPSCs by Technology
13.3 Global Market for iPSCs by Biomedical Application
13.4 Global Market for iPSCs by Derived Cell Type
13.5 Market Drivers
13.5.1 Current Drivers Impacting the iPSC Marketplace
13.6 Market Restraints
13.6.1 Economic Issues
13.6.2 Genomic Instability
13.6.3 Immunogenicity
13.6.4 Biobanking
14. Company Profiles
14.1 Accellta
14.1.1 Technology
14.1.2 Maxells
14.1.3 Singles
14.1.4 Diffentiation
14.1.5 Services
14.2 Addgene, Inc.
14.2.1 Viral Plasmids
14.3 Allele Biotechnology, Inc.
14.3.1 iPSC Reprogramming and Differentiation
14.3.2 Cgmp Facility
14.4 Alstem, Inc.
14.4.1 Services
14.4.2 iPSC-Related Products
14.4.3 Human Ips Cell Lines
14.4.4 Inducible Ips Cell Lines
14.4.5 Isogenic Ips Cell Lines
14.4.6 Knockout Cell Lines
14.5 Altos Labs
14.6 Ams Biotechnology Ltd. (Amsbio)
14.6.1 iPSC-Derived Cells and Differentiation Kits
14.6.2 iPSC-Derived Excitatory Neurons
14.6.3 iPSC-Derived Dopaminergic Neurons
14.6.4 iPSC-Derived Gabaergic Neurons
14.6.5 iPSC-Derived Cholinergic Neurons
14.6.6 iPSC-Derived Skeletal Muscle
14.7 Aspen Neuroscience, Inc.
14.7.1 Aspen’S Clinical Pipeline
14.8 Astellas Pharma, Inc.
14.8.1 Leading Program
14.9 Avery Therapeutics
14.9.1 Mycrdia
14.10 Axol Bioscience Ltd.
14.10.1 iPSC-Derived Cells
14.10.2 Disease Models
14.10.3     Services
14.10.4 Custom Cell Services
14.10.5 Stem Cell Reprogramming
14.10.6 Genome Editing
14.10.7 Stem Cell Differentiation
14.11 Bit.Bio
14.11.1 Opti-Ox Reprogramming Technology
14.11.2 Iocells
14.11.3 Iowild Type Cells
14.11.4 Ioglutamatergic Neurons
14.11.5 Ioskeletal Myocytes
14.11.6 Iogabaergic Neurons
14.11.7 Iodisease Models
14.11.8 Ioglutamatergic Neurons Htt50Cagwt
14.12 Bluerock Therapeutics
14.12.1 Cell + Gene Platform
14.13 Brainxell
14.13.1 Products
14.13.1.1 Spinal Motor Neurons
14.13.1.2 Midbrain Dopaminergic Neurons
14.13.1.3 Cortical Glutamatergic Neurons
14.13.1.4 Mixed Cortical Neurons
14.13.1.5 Cortical Astrocytes
14.13.1.6 Layer V Glutamatergic Neurons
14.13.1.7 Cortical Gabaergic Neurons
14.13.1.8 Microglia
14.13.1.9 Medium Spiny Neurons
14.13.1.10 Spinal Astrocytes
14.14 Brooklyn Immuno Therapeutics
14.14.1 Synthetic Mrna
14.14.2 Non-Viral Nucleic Acid Delivery
14.14.3 Cellular Reprogramming
14.14.4 Gene Editing
14.15 Catalent Biologics
14.15.1 Human iPSCs
14.16 Celogics, Inc.
14.16.1 Celo.Cardiomyocytes
14.17 Cellaria
14.17.1 Lung Cancer Cell Models
14.17.2 Breast Cancer Cell Models
14.17.3 Colon Cancer Cell Lines
14.17.4 Ovarian Cancer Cell Lines
14.17.5 Pancreatic Cancer Cell Lines
14.17.6 Cancer Research Custom Services
14.17.7 Stem Cell Services
14.18 Cellgenix, GmbH
14.18.1 Products
14.19 Cellino Biotech
14.19.1 Cellino’S Technology Platform
14.20 Cellular Engineering Technologies (Cet)
14.20.1 Products
14.20.2 Ips Cell Lines
14.20.3 Drug Discovery Services
14.20.4 iPSC Reprogramming Services
14.21 Censo Biotechnologies, Ltd.
14.21.1 Neuroinflammation
14.21.2 Inflammation
14.21.3 Neurobiology
14.22 Century Therapeutics, Inc.
14.22.1 Cell Therapy Platform
14.22.2 Century’S Pipeline
14.23 Citius Pharmaceuticals, Inc.
14.23.1 Stem Cell Platform of Imscs
14.24 Clade Therapeutics
14.25 Creative Bioarray
14.25.1 iPSC Reprogramming Kits
14.25.2 Qualistem Episomal iPSC Reprogramming Kit
14.25.3 Qualistem Rna iPSC Reprogramming Kit
14.25.4 Qualistem Retrovirus iPSC Reprogramming Kit
14.25.5 Qualistem Lentivirus iPSC Reprogramming Kit
14.25.6 Qualistem  iPSC Protein Reprogramming Kit
14.25.7 iPSC Characterization Kits
14.25.8 Alkaline Phosphatase Staining Assay
14.25.9 Pluripotency Markers (Protein)
14.25.10 Pluripotency Markers (Mrna)
14.25.11 iPSC Differentiation Kits
14.25.12 Qualistem Ips Cell Cardiomyocyte Differentiation Kit
14.25.13 Qualistem Human Ips Cell Dopaminergic Neuron Differentiation Kit
14.25.14 Qualistem Ips Cell Neural Progenitor Differentiation Kit
14.25.15 Qualistem Ips Cell Endoderm Differentiation Kit
14.25.16 Qualistem Ips Cell Ectoderm Differentiation Kit
14.25.17 Qualistem Ips Cell Mesoderm Differentiation Kit
14.25.18 Qualistem Ips Cell Hepatocyte Differentiation Kit
14.25.19 iPSC Myogenic Progenitor Differentiation Kit
14.26 Curi Bio
14.26.1 Disease Model Development
14.26.2 Assay Development
14.26.3 Discovery
14.26.4 Cell Repositories
14.27 Cynata Therapeutics Ltd.
14.27.1 Cymerus Platform
14.27.2 Clinical Development
14.27.2.1 Graft Vs. Host Disease
14.27.2.2 Critical Limb Ischemia
14.27.2.3 Osteoarthritis
14.27.2.4 Acute Respiratory Syndrome
14.27.2.5 Diabetic Wounds
14.27.2.6 Preclinical Development
14.27.2.7 Idiopathic Pulmonary Fibrosis
14.27.2.8 Renal Transplantation
14.27.2.9 Asthma
14.27.2.10 Heart Attack
14.27.2.11 Coronary Artery Disease
14.28 Cytovia Therapeutics
14.28.1 Technology
14.28.2 Ink & Car-Ink Cells
14.28.3 Flex-Nk Cell Engagers
14.29 Definigen
14.29.1 Optidiff iPSC Platform
14.29.2 Services
14.29.2.1 Phenotypic Screening Services
14.29.2.2 iPSC Differentiation Services
14.29.2.3 Disease Modeling Services
14.29.3 Products
14.29.3.1 Hepatocyte Wt
14.29.3.2 Nafld iPSC-Derived Hepatocytes
14.29.3.3 Gsd1A Disease Modeled Hepatocytes
14.29.3.4 A1Atd Disease Modeled Hepatocytes
14.29.3.5 Hepatocyte Familial Hypercholesterolemia (Fh)
14.29.3.6 Custom Model Development
14.29.3.7 Nafld Pnpla3
14.29.3.8 Nafld Tm6Sf2 Disease Modeled Hepatocytes
14.29.3.9 Intestinal Organoids
14.29.3.10 Intestinal Monolayer
14.29.3.11 Pancreatic Beta Cells (Wt)
14.29.3.12 Mody3 Diabetes
14.29.3.13 Neonatal Diabetes Pancreatic Cells
14.30 Editas Medicine
14.30.1 iPSC-Derived Nk Cells
14.31 Elevatebio
14.31.1 Technologies
14.32 Elixirgen Scientific, Inc.
14.32.1 Technology
14.32.2 Services
14.32.3 iPSC Products
14.32.4 Reagents
14.33 Evia Bio
14.33.1 iPSCs Cryopreservation Solutions
14.34 Evotec A.G.
14.34.1 iPSCs Platform
14.34.2 Drug Discoveries
14.35 Exacis Biotherapeutics
14.35.1 Exacells
14.36 Eyestem
14.36.1 Eyecyte-Rpe
14.37 Fate Therapeutics
14.37.1 iPSCs Platform
14.37.2 Pipeline
14.37.3 Collaborations
14.37.3.1 Janssen Biotech
14.37.3.2 Ono Pharmaceutical
14.38 Fujifilm Cellular Dynamics, Inc. (Fcdi)
14.38.1 Products
14.38.2 Mycell Custom Services
14.38.3 Disease Modeling Applications
14.38.4 Drug Discovery Applications
14.38.5 Applications in Toxicity Testing
14.39 Heartseed, Inc.
14.39.1 Technology
14.40 Hebecell
14.40.1 Technology
14.41 Helios K.K.
14.42 Hera Biolabs
14.42.1 Services
14.42.2 Products
14.42.3 Piggybac Transposase/Transposon
14.43 Hopstem Biotechnology
14.43.1 Research & Development
14.43.2 Product Pipeline
14.44 Implant Therapeutics, Inc.
14.44.1 Services
14.45 Ips Portal, Inc
14.45.1 Services
14.45.1.1 Research Support and Contract Testing Services
14.45.1.2 Development Support Services
14.45.2 Business Support
14.46 I Peace, Inc.
14.46.1 Mass Production of iPSCs
14.47 Ixcells Biotechnologies
14.47.1 Products
14.47.2 Services
14.47.3 Ips Cell Generation
14.47.4 Genome Editing
14.47.5 iPSC Differentiation
14.48 Kytopen
14.48.1 Flowfect Technology
14.49 Lizarbio Therapeutics
14.49.1 Pipeline
14.50 Lonza Group, Ltd.
14.50.1 iPSC Manufacturing Expertise
14.50.2 Nucleofector Technology
14.51 Matricelf
14.52 Merck/Sigma Aldrich
14.52.2 Merck’S iPSC Products and Services
14.53 Megakaryon Corporation
14.53.1 Technology
14.53.2 Research and Development Pipeline
14.53.3 Cryopreservable Megakaryon Strain
14.53.4 Treatable Diseases by Products from Megakaryon
14.54 Metrion Biosciences, Ltd.
14.54.1 Cardiac Safety Screening Services
14.54.2 Neuroscience Assay Services
14.54.3 Cardiac Assay Services
14.54.4 Neuroscience Translational Assay Services
14.54.5 Integrated Drug Discovery Service
14.55 Mogrify
14.55.1 Mogrify Platform
14.55.2 Epimogrify Platform
14.56 Ncardia
14.56.1 iPSC Platform
14.56.2 Human iPSC-Derived Cell Models
14.56.3 Drug Discovery Solutions
14.56.4 Developing iPSC-Derived Cell Types
14.56.5 Assay Development
14.56.6 High-Throughput Screening
14.57 Neucyte
14.57.1 Synfire Technology
14.58 Neukio Biotherapeutics
14.58.1 iPSC-Car-Nk
14.59 Newcells Biotech, Ltd
14.59.1 Retinal Platform
14.59.2 Kidney Platform
14.59.3 Lung Model
14.60 Nexel Co. Ltd.
14.60.1 Cardiosight-S
14.60.2 Hepatocyte-S
14.60.3 Neurosight-S
14.60.4 Nexst Cardiac Safety Service
14.61 Orizuru Therapeutics, Inc.
14.61.1 Icm Project
14.61.2 Ipic Project
14.62 Phenocell Sas
14.62.1 Cells and Kits
14.62.2 R&D Outsourcing Services
14.63 Platelet Biogenesis
14.63.1 Technology
14.64 Pluristyx
14.64.1 Rtd and Rtu Technologies
14.64.2 Products
14.64.3 Services
14.65 Reneuron
14.65.1 Technology Platform
14.66 Reprocell Usa, Inc.
14.66.1 Rna Reprogramming Kit
14.66.2 Nutristem Culture Medium for Human iPSCs and Es Cells
14.66.3 Induced Pluripotent Stem Cells
14.66.4 Stemrna Neuro
14.66.5 iPSCs Master Cell Bank
14.67 Rxcell, Inc.
14.67.1 Services
14.68 Scg Cell Therapy Pte Ltd.
14.68.1 Acquisition of Technology
14.69 Shoreline Biosciences
14.69.1 Ink Cell Platform
14.69.2 iPSC-Derived Imacs
14.70 Stemson Therapeutics
14.70.1 Hair Follicle Biology
14.71 Stemina Biomarker Discovery
14.71.1 Cardio Quickpredict
14.71.2 Devtox Quickpredict
14.72 Synthego Corp.
14.72.1 Knockout iPSCs
14.72.2 Knock-In iPSCs
14.73 Tempo Bioscience
14.73.1 Human iPSC-Derived Sensory Neurons
14.73.2 Human Ips-Derived Schwann Cells
14.73.3 Human Ips-Derived Phagocytes
14.73.4 Human iPSC-Derived Cd14+ Monocytes
14.73.5 Human iPSC-Derived Cardiomyocytes
14.73.6 Hipsc-Derived Kidney Proximal Tubules and Podocyte 3D Spheroids
14.73.7 Human iPSC-Derived Osteoblasts
14.73.8 Human iPSC-Derived Mscs
14.73.9 Human iPSC-Derived Retinal Pigment Epithelials
14.73.10 Human Ips-Derived Motor Neurons
14.73.11 Human iPSC-Derived Microglia
14.73.12 Human iPSC-Derived Keratinocytes
14.73.13 Human iPSC-Derived Melanocytes
14.73.14 Human iPSC-Derived Dopaminergic Neurons
14.73.15 Human iPSC-Derived Cortical Neurons
14.73.16 Human iPSC-Derived Oligodendrocyte Progenitor Cells (Opcs)
14.73.17 Human iPSC-Derived Astrocytes
14.73.18 Human iPSC-Derived Neural Progenitor Cells
14.74 Thyas, Co. Ltd.
14.74.1 Itcr-T (iPSC-Derived Tcr-T)
14.74.2 Icar-Nk/Ilc (iPSC-Derived Car-Nk/Ilc)
14.74.3 Thya’S Product Pipeline
14.75 Universal Cells
14.75.1 Technology
14.75.2 Editing the Genome Without Breaking It
14.75.3 Cells for Every Organ
14.76 Viacyte, Inc.
14.76.1 Pec-01 Cells
14.76.2 Device Engineering
14.77 Vita Therapeutics
14.77.1 Technology
14.77.2 Vta-100
14.78 Xcell Science, Inc.
14.78.1 Cell Products
14.78.2 Control Lines
14.78.3 Services
14.79 Yashraj Biotechnology, Ltd.
14.79.1 iPSC and Differentiated Derivatives
14.79.1.1 iPSC-Derived Human Cardiomyocytes
14.79.1.2 iPSC-Derived Hepatocytes
14.79.1.3 iPSC-Derived Astrocytes
14.79.1.4 iPSC-Derived Forebrain Motor Neurons
14.79.1.5 iPSC-Derived Endothelial Cells
14.79.1.6 iPSC-Derived Midbrain Dopaminergic Neurons
14.80 Yipcell
14.80.1 R&D Programs
14.80.2 Miuchon
14.80.3 Miukin
14.80.4 Miuron 

Companies Mentioned

  •  Accellta 
  •  Addgene, Inc. 
  •  Allele Biotechnology, Inc. 
  •  Alstem, Inc. 
  •  Altos Labs 
  •  Ams Biotechnology Ltd. (Amsbio) 
  •  Aspen Neuroscience, Inc. 
  •  Astellas Pharma, Inc. 
  •  Avery Therapeutics 
  •  Axol Bioscience Ltd. 
  •  Bit.Bio 
  •  Bluerock Therapeutics 
  •  Brainxell 
  •  Brooklyn Immuno Therapeutics 
  •  Catalent Biologics 
  •  Cellaria 
  •  Cellgenix, GmbH 
  •  Cellino Biotech 
  •  Cellular Engineering Technologies (Cet) 
  •  Celogics, Inc. 
  •  Censo Biotechnologies, Ltd.  
  •  Century Therapeutics, Inc. 
  •  Citius Pharmaceuticals, Inc. 
  •  Clade Therapeutics 
  •  Creative Bioarray 
  •  Curi Bio 
  •  Cynata Therapeutics Ltd. 
  •  Cytovia Therapeutics 
  •  Definigen  
  •  Editas Medicine 
  •  Elevatebio 
  •  Elixirgen Scientific, Inc. 
  •  Evia Bio 
  •  Evotec A.G. 
  •  Exacis Biotherapeutics 
  •  Eyestem 
  •  Fate Therapeutics  
  •  Fujifilm Cellular Dynamics, Inc. (Fcdi) 
  •  Heartseed, Inc. 
  •  Hebecell 
  •  Helios K.K. 
  •  Hera Biolabs 
  •  Hopstem Biotechnology 
  •  I Peace, Inc. 
  •  Implant Therapeutics, Inc. 
  •  Ips Portal, Inc 
  •  Ixcells Biotechnologies 
  •  Kytopen 
  •  Lizarbio Therapeutics 
  •  Lonza Group, Ltd.  
  •  Matricelf 
  •  Megakaryon Corporation 
  •  Merck/Sigma Aldrich 
  •  Metrion Biosciences, Ltd. 
  •  Mogrify 
  •  Ncardia 
  •  Neucyte 
  •  Neukio Biotherapeutics 
  •  Newcells Biotech, Ltd 
  •  Nexel Co. Ltd. 
  •  Orizuru Therapeutics, Inc. 
  •  Phenocell Sas 
  •  Pluristyx 
  •  Reneuron 
  •  Reprocell Usa, Inc. 
  •  Rxcell, Inc. 
  •  Shoreline Biosciences 
  •  Stemson Therapeutics 
  •  Synthego Corp. 
  •  Tempo Bioscience 
  •  Thyas, Co. Ltd. 
  •  Viacyte, Inc. 
  •  Vita Therapeutics 
  •  Xcell Science, Inc. 
  •  Yashraj Biotechnology, Ltd. 
  •  Yipcell 

Methodology

The content and statistics contained within the publisher's reports are compiled using a broad range of sources, as described below.

Input Sources

  • Clinical Trial Databases (ClinicalTrials.gov, International Clinical Trials Registry Platform, European Union Clinical Trials Register, Chinese Clinical Trial Registry, Others)
  • Scientific Publication Databases (PubMed, Highwire Press, Google Scholar)
  • Patent Databases (United States Patent and Trade Office, World Intellectual Property Organization, Google Patent Search)
  • Grant Funding Databases (RePORT Database, CIRM, MRC, Wellcome Trust - UK, Others)
  • Product Launch Announcements (Trade Journals, Google News)
  • Industry Events (Google News, Google Alerts, Press Releases)
  • Company News (SEC Filings, Investor Publications, Historical Performance)
  • Social Analytics (Google Adwords, Google Trends, Twitter, Topsy.com, Hashtagify.me, BuzzSumo.com)
  • Interviews with Stem Cell Industry Leaders

Research & Analysis Methodologies

The publisher employs the following techniques for deriving its market research:

  • Historical Databases: As the first and only market research firm to specialize in the stem cell industry, the publisher has 13+ years of historical data on each segment of the stem cell the industry. This provides an extremely rare and robust database for establishing market size determinations, as well as making future market predictions.
  • Prolific Interviews with Industry Leaders: As the global leader in stem cell industry data, the publisher has interviewed hundreds of leaders from across the stem cell industry, including the CEO of FUJIFILM CDI, FUJIFILM Irvine Scientific, Pluristem Therapies, Celularity, and many others.
  • Industry Relationships: The research team and its President/Founder, Cade Hildreth, Chair and present at a wide range of stem cell industry events, including Phacilitate's Advanced Therapies Week, World Stem Cell Summit (WSCS), Perinatal Stem Cell Society Congress, AABB's International Cord Blood Symposium (ICBS), and other events hosted within the U.S. and worldwide.
  • Global Integrated Feedback: Because the publisher maintains the world's largest stem cell industry news site that is read by nearly a million unique readers per year and the company has large social media audiences (25.7K+ followers on Linked, 21.2K+ followers on Twitter, and 4.3K+ followers on Facebook), the publisher is able to publish content relevant to the industry and receive immediate feedback/input from a global community of readers. In short, the publisher's data is crowd-sourced from market participants worldwide, including those in diverse geographic regions.
  • Preliminary Research: In addition to the interviews described above, the publisher conducts market surveys, executes social media polls, and aggregates market data from stem cell industry announcements, press releases, and corporate filings/presentations.
  • Secondary Research: The publisher summarizes, collects and synthesizes existing market research that is relevant to the market area of interest.
  • Future Projections: Using the resources described above, the publisher is uniquely positioned to make future projections about market size, market growth by segment, market trends, technology evolution, funding activities (financing rounds, M&A, and IPOs), and importantly, market leadership (market share by company).
 

Loading
LOADING...